Share Price and Basic Stock Data
Last Updated: November 3, 2025, 9:15 pm
| PEG Ratio | -0.55 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Lasa Supergenerics Ltd operates in the specialty chemicals segment, with a current market capitalization of ₹53.2 Cr and a share price of ₹10.6. The company has experienced fluctuating sales over recent quarters, with revenue reported at ₹29 Cr in June 2022, peaking at ₹35 Cr in March 2023 before declining to ₹24 Cr in September 2023. Notably, the trailing twelve months (TTM) sales stood at ₹132 Cr, reflecting a downward trend compared to previous years, where sales were ₹137 Cr in FY 2022 and ₹130 Cr in FY 2023. This decline is indicative of challenges in maintaining growth in a competitive industry that often sees volatility. The company’s operational performance has been marked by negative operating profit margins (OPM) in several quarters, with an OPM of -2% reported for the most recent period. This trend raises concerns about the company’s ability to sustain revenue growth amidst increasing competition and operational challenges.
Profitability and Efficiency Metrics
The profitability of Lasa Supergenerics has been under significant pressure, evidenced by a reported net loss of ₹33 Cr in FY 2023, which worsened to ₹22 Cr in FY 2025. Operating profit margins have fluctuated, with a peak of 13% in June 2023, but a subsequent decline leading to a negative OPM of -2% in June 2025. The return on equity (ROE) is low, recorded at 1.01%, and return on capital employed (ROCE) at 1.00%, indicating inefficiencies in generating returns for shareholders. The company’s interest coverage ratio (ICR) is relatively robust at 4.19x, suggesting that it can comfortably cover its interest obligations despite its profitability challenges. The cash conversion cycle (CCC) stands at 53 days, which is relatively efficient compared to the industry average, indicating that the company can manage its working capital effectively. However, the ongoing losses and declining margins pose risks to long-term sustainability.
Balance Sheet Strength and Financial Ratios
Lasa Supergenerics maintains a cautious approach towards its balance sheet, with total borrowings reported at ₹2 Cr, a significant reduction from ₹22 Cr in FY 2024. This reduction in debt strengthens the company’s financial position, reflected in a total debt to equity ratio of 0.03x, indicating low leverage. Reserves have decreased to ₹34 Cr in FY 2025 from ₹68 Cr in FY 2023, which may limit the company’s capacity for investments in growth or R&D. The book value per share has also declined from ₹36.54 in FY 2022 to ₹16.71 in FY 2025, reflecting the challenges in equity value amidst ongoing losses. The current ratio is favorable at 1.90, suggesting adequate liquidity to meet short-term obligations. However, the declining net profit margins, which stood at -10.35% in FY 2025, highlight the ongoing struggles with profitability despite the relatively strong balance sheet.
Shareholding Pattern and Investor Confidence
The shareholding structure of Lasa Supergenerics reveals a stable promoter holding of 53.65%, which has remained unchanged since March 2023. Institutional interest appears minimal, with foreign institutional investors (FIIs) holding only 0.47% of the company, indicating low confidence from institutional investors in the company’s growth prospects. Public shareholding stands at 45.88%, reflecting a diverse investor base, albeit with declining numbers of shareholders from 29,692 in September 2022 to 28,115 in June 2025. This trend may suggest waning confidence among retail investors. The absence of dividends in recent years, alongside deteriorating profitability, further complicates the investor sentiment. The company’s ability to regain investor confidence will depend on improving operational efficiencies and returning to profitability.
Outlook, Risks, and Final Insight
Lasa Supergenerics faces a challenging environment, with the potential for recovery hinging on its ability to enhance operational efficiency and profitability. Key strengths include a manageable debt level and a solid promoter stake, indicating a committed management team. However, risks are pronounced, including declining sales, negative profit margins, and low investor confidence, which could impede growth prospects. The company must navigate these challenges by focusing on operational improvements and strategic initiatives to regain market share. Future scenarios could involve a turnaround in profitability if the company successfully implements cost controls and enhances its product offerings, or continued struggles if current trends persist. Stakeholders should closely monitor the company’s quarterly performance to gauge any signs of recovery or further decline.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lasa Supergenerics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 479 Cr. | 52.3 | 86.7/42.6 | 29.2 | 20.0 | 0.77 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 36.5 Cr. | 74.4 | 104/56.0 | 16.3 | 87.4 | 1.34 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.0 Cr. | 720 | 1,178/600 | 53.2 | 670 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,686 Cr. | 81.3 | 114/78.0 | 24.6 | 20.7 | 0.62 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 762 Cr. | 303 | 453/241 | 27.3 | 91.1 | 0.82 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,894.12 Cr | 741.84 | 48.30 | 178.98 | 0.40% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 34 | 32 | 35 | 31 | 24 | 27 | 23 | 31 | 39 | 33 | 39 | 20 |
| Expenses | 37 | 34 | 34 | 31 | 27 | 23 | 26 | 27 | 29 | 39 | 33 | 36 | 21 |
| Operating Profit | -8 | -0 | -2 | 4 | 4 | 1 | 1 | -4 | 2 | 1 | 0 | 3 | -0 |
| OPM % | -28% | -1% | -8% | 12% | 13% | 4% | 4% | -17% | 6% | 2% | 1% | 9% | -2% |
| Other Income | 0 | -2 | 1 | -19 | 0 | 0 | 0 | -9 | 0 | 2 | 9 | -22 | -20 |
| Interest | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 2 |
| Profit before tax | -11 | -7 | -5 | -19 | 1 | -2 | -2 | -16 | -2 | -1 | 6 | -22 | -23 |
| Tax % | 8% | -2% | -4% | -22% | 581% | -99% | -30% | -4% | 47% | 147% | 7% | -35% | -6% |
| Net Profit | -12 | -7 | -5 | -15 | -5 | -0 | -1 | -15 | -3 | -3 | 5 | -14 | -21 |
| EPS in Rs | -2.97 | -1.63 | -1.21 | -2.99 | -0.99 | -0.00 | -0.29 | -3.05 | -0.54 | -0.64 | 1.10 | -2.85 | -4.22 |
Last Updated: August 20, 2025, 7:50 am
Below is a detailed analysis of the quarterly data for Lasa Supergenerics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 19.00 Cr..
- For Expenses, as of Jun 2025, the value is 21.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 36.00 Cr. (Mar 2025) to 21.00 Cr., marking a decrease of 15.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Jun 2025, the value is -2.00%. The value appears to be declining and may need further review. It has decreased from 9.00% (Mar 2025) to -2.00%, marking a decrease of 11.00%.
- For Other Income, as of Jun 2025, the value is -20.00 Cr.. The value appears strong and on an upward trend. It has increased from -22.00 Cr. (Mar 2025) to -20.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -23.00 Cr.. The value appears to be declining and may need further review. It has decreased from -22.00 Cr. (Mar 2025) to -23.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is -6.00%. The value appears to be increasing, which may not be favorable. It has increased from -35.00% (Mar 2025) to -6.00%, marking an increase of 29.00%.
- For Net Profit, as of Jun 2025, the value is -21.00 Cr.. The value appears to be declining and may need further review. It has decreased from -14.00 Cr. (Mar 2025) to -21.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -4.22. The value appears to be declining and may need further review. It has decreased from -2.85 (Mar 2025) to -4.22, marking a decrease of 1.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:57 am
| Metric | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 132 |
| Expenses | -0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 128 |
| Operating Profit | -0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | 4 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | 4% | 3% | |
| Other Income | -0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -31 |
| Interest | -0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 2 |
| Depreciation | -0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 11 |
| Profit before tax | -0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -40 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | ||
| Net Profit | -0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -33 |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -6.61 | ||
| Dividend Payout % | -0% | -0% | -0% | -0% | 4% | -24% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 500.00% | -200.00% | 133.33% | 475.00% | -121.74% | -680.00% | 43.59% | 31.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | -700.00% | 333.33% | 341.67% | -596.74% | -558.26% | 723.59% | -11.77% |
Lasa Supergenerics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | 1% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -28% |
| TTM: | 133% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -38% |
| 1 Year: | -73% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 9:35 am
Balance Sheet
Last Updated: June 16, 2025, 11:48 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 |
Below is a detailed analysis of the balance sheet data for Lasa Supergenerics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 50.00 Cr..
- For Reserves, as of Mar 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 47.00 Cr. (Mar 2024) to 34.00 Cr., marking a decrease of 13.00 Cr..
- For Borrowings, as of Mar 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 22.00 Cr. (Mar 2024) to 2.00 Cr., marking a decrease of 20.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing). It has decreased from 32.00 Cr. (Mar 2024) to 16.00 Cr., marking a decrease of 16.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 102.00 Cr.. The value appears to be improving (decreasing). It has decreased from 151.00 Cr. (Mar 2024) to 102.00 Cr., marking a decrease of 49.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 68.00 Cr.. The value appears to be declining and may need further review. It has decreased from 110.00 Cr. (Mar 2024) to 68.00 Cr., marking a decrease of 42.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 3.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2024) to 33.00 Cr., marking a decrease of 6.00 Cr..
- For Total Assets, as of Mar 2025, the value is 102.00 Cr.. The value appears to be declining and may need further review. It has decreased from 151.00 Cr. (Mar 2024) to 102.00 Cr., marking a decrease of 49.00 Cr..
Notably, the Reserves (34.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2016n n 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -70.00 | -66.00 | -74.00 | -18.00 | 28.00 | -4.00 | -28.00 | -20.00 | 4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Diluted EPS (Rs.) | -2.95 | -4.34 | -7.71 | -1.30 | 5.60 |
| Cash EPS (Rs.) | -0.49 | -2.21 | -5.03 | 2.12 | 9.49 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.71 | 19.30 | 23.61 | 36.54 | 39.07 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.25 | 0.25 |
| Revenue From Operations / Share (Rs.) | 28.43 | 20.82 | 25.86 | 33.71 | 49.76 |
| PBDIT / Share (Rs.) | 2.25 | 0.45 | -0.95 | 3.86 | 11.62 |
| PBIT / Share (Rs.) | -0.20 | -1.68 | -3.63 | 0.41 | 7.73 |
| PBT / Share (Rs.) | -3.87 | -3.81 | -8.44 | -1.53 | 7.25 |
| Net Profit / Share (Rs.) | -2.94 | -4.34 | -7.71 | -1.32 | 5.60 |
| PBDIT Margin (%) | 7.91 | 2.17 | -3.69 | 11.44 | 23.36 |
| PBIT Margin (%) | -0.71 | -8.05 | -14.05 | 1.23 | 15.54 |
| PBT Margin (%) | -13.60 | -18.31 | -32.62 | -4.52 | 14.57 |
| Net Profit Margin (%) | -10.35 | -20.82 | -29.80 | -3.91 | 11.25 |
| Return on Networth / Equity (%) | -17.62 | -22.47 | -32.65 | -3.61 | 14.33 |
| Return on Capital Employeed (%) | -1.21 | -8.24 | -15.03 | 1.08 | 18.79 |
| Return On Assets (%) | -14.53 | -14.40 | -23.57 | -2.69 | 10.95 |
| Long Term Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 1.13 | 0.66 | 0.71 | 0.67 | 0.92 |
| Current Ratio (X) | 1.90 | 0.77 | 0.91 | 1.65 | 1.59 |
| Quick Ratio (X) | 0.46 | 0.38 | 0.59 | 1.39 | 1.16 |
| Inventory Turnover Ratio (X) | 4.97 | 4.81 | 8.67 | 6.13 | 4.69 |
| Interest Coverage Ratio (X) | 4.19 | 1.17 | -1.15 | 389.33 | 24.08 |
| Interest Coverage Ratio (Post Tax) (X) | 1.34 | -5.71 | -3.50 | 62.86 | 12.60 |
| Enterprise Value (Cr.) | 86.20 | 108.58 | 90.15 | 152.41 | 239.23 |
| EV / Net Operating Revenue (X) | 0.60 | 1.04 | 0.69 | 1.11 | 1.18 |
| EV / EBITDA (X) | 7.64 | 47.93 | -18.82 | 9.71 | 5.06 |
| MarketCap / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| Price / BV (X) | 1.01 | 1.14 | 0.78 | 1.14 | 1.53 |
| Price / Net Operating Revenue (X) | 0.59 | 1.05 | 0.71 | 1.24 | 1.20 |
| EarningsYield | -0.17 | -0.19 | -0.41 | -0.03 | 0.09 |
After reviewing the key financial ratios for Lasa Supergenerics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.95. This value is below the healthy minimum of 5. It has increased from -4.34 (Mar 24) to -2.95, marking an increase of 1.39.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.49. This value is below the healthy minimum of 3. It has increased from -2.21 (Mar 24) to -0.49, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.71. It has decreased from 19.30 (Mar 24) to 16.71, marking a decrease of 2.59.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 28.43. It has increased from 20.82 (Mar 24) to 28.43, marking an increase of 7.61.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 2.25, marking an increase of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.20. This value is below the healthy minimum of 0. It has increased from -1.68 (Mar 24) to -0.20, marking an increase of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.87. This value is below the healthy minimum of 0. It has decreased from -3.81 (Mar 24) to -3.87, marking a decrease of 0.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.94. This value is below the healthy minimum of 2. It has increased from -4.34 (Mar 24) to -2.94, marking an increase of 1.40.
- For PBDIT Margin (%), as of Mar 25, the value is 7.91. This value is below the healthy minimum of 10. It has increased from 2.17 (Mar 24) to 7.91, marking an increase of 5.74.
- For PBIT Margin (%), as of Mar 25, the value is -0.71. This value is below the healthy minimum of 10. It has increased from -8.05 (Mar 24) to -0.71, marking an increase of 7.34.
- For PBT Margin (%), as of Mar 25, the value is -13.60. This value is below the healthy minimum of 10. It has increased from -18.31 (Mar 24) to -13.60, marking an increase of 4.71.
- For Net Profit Margin (%), as of Mar 25, the value is -10.35. This value is below the healthy minimum of 5. It has increased from -20.82 (Mar 24) to -10.35, marking an increase of 10.47.
- For Return on Networth / Equity (%), as of Mar 25, the value is -17.62. This value is below the healthy minimum of 15. It has increased from -22.47 (Mar 24) to -17.62, marking an increase of 4.85.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.21. This value is below the healthy minimum of 10. It has increased from -8.24 (Mar 24) to -1.21, marking an increase of 7.03.
- For Return On Assets (%), as of Mar 25, the value is -14.53. This value is below the healthy minimum of 5. It has decreased from -14.40 (Mar 24) to -14.53, marking a decrease of 0.13.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.13. It has increased from 0.66 (Mar 24) to 1.13, marking an increase of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has increased from 0.77 (Mar 24) to 1.90, marking an increase of 1.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.38 (Mar 24) to 0.46, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.97. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 4.97, marking an increase of 0.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.19. This value is within the healthy range. It has increased from 1.17 (Mar 24) to 4.19, marking an increase of 3.02.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 3. It has increased from -5.71 (Mar 24) to 1.34, marking an increase of 7.05.
- For Enterprise Value (Cr.), as of Mar 25, the value is 86.20. It has decreased from 108.58 (Mar 24) to 86.20, marking a decrease of 22.38.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.60, marking a decrease of 0.44.
- For EV / EBITDA (X), as of Mar 25, the value is 7.64. This value is within the healthy range. It has decreased from 47.93 (Mar 24) to 7.64, marking a decrease of 40.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For Price / BV (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.14 (Mar 24) to 1.01, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.05 (Mar 24) to 0.59, marking a decrease of 0.46.
- For EarningsYield, as of Mar 25, the value is -0.17. This value is below the healthy minimum of 5. It has increased from -0.19 (Mar 24) to -0.17, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lasa Supergenerics Ltd:
- Net Profit Margin: -10.35%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.21% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -17.62% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.34
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.8 (Industry average Stock P/E: 48.3)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.35%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722 | investor@lasalabs.com http://www.lasalabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Omkar Pravin Herlekar | Chairman & Managing Director |
| Mr. Umesh S Pawar | Executive Director |
| Mr. Ajay Sukhwani | Independent Director |
| Ms. Manali Bhagtani | Independent Director |
| Ms. Ekta Gurnasinghani | Independent Director |
| Mr. Hardesh Tolani | Independent Director |
FAQ
What is the intrinsic value of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd's intrinsic value (as of 03 November 2025) is 2.31 which is 79.74% lower the current market price of 11.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 59.0 Cr. market cap, FY2025-2026 high/low of 31.4/8.16, reserves of ₹34 Cr, and liabilities of 102 Cr.
What is the Market Cap of Lasa Supergenerics Ltd?
The Market Cap of Lasa Supergenerics Ltd is 59.0 Cr..
What is the current Stock Price of Lasa Supergenerics Ltd as on 03 November 2025?
The current stock price of Lasa Supergenerics Ltd as on 03 November 2025 is 11.4.
What is the High / Low of Lasa Supergenerics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lasa Supergenerics Ltd stocks is 31.4/8.16.
What is the Stock P/E of Lasa Supergenerics Ltd?
The Stock P/E of Lasa Supergenerics Ltd is 16.8.
What is the Book Value of Lasa Supergenerics Ltd?
The Book Value of Lasa Supergenerics Ltd is 16.7.
What is the Dividend Yield of Lasa Supergenerics Ltd?
The Dividend Yield of Lasa Supergenerics Ltd is 0.00 %.
What is the ROCE of Lasa Supergenerics Ltd?
The ROCE of Lasa Supergenerics Ltd is 1.00 %.
What is the ROE of Lasa Supergenerics Ltd?
The ROE of Lasa Supergenerics Ltd is 1.01 %.
What is the Face Value of Lasa Supergenerics Ltd?
The Face Value of Lasa Supergenerics Ltd is 10.0.